SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001193125-22-309510 from HTG MOLECULAR DIAGNOSTICS, INC (HTGMQ) (CIK 0001169987)

HTG MOLECULAR DIAGNOSTICS, INC (HTGMQ) (CIK 0001169987)
Date: Dec. 21, 2022 · CIK: 0001169987 · Accession: 0001193125-22-309510

AI Filing Summary & Sentiment

File numbers found in text: 333-268681

Date
December 21, 2022
Author
H.C. WAINWRIGHT & CO., LLC
Form
CORRESP
Company
HTG MOLECULAR DIAGNOSTICS, INC (HTGMQ) (CIK 0001169987)

Letter

Re: HTG Molecular Diagnostics, Inc.

December 21, 2022

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporate Finance

Washington, DC 20549

Registration Statement on Form S-1 (Registration No. 333-268681) -

Concurrence in Acceleration Request

Ladies and Gentlemen:

H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pursuant to the registration statement on Form S-1 (333-268681) (the “Registration Statement”), hereby concurs in the request by HTG Molecular Diagnostics, Inc. (the “Company”) that the effective date of the above-referenced registration statement be accelerated to 1:00 P.M. (Eastern Time), or as soon as practicable thereafter, on December 21, 2022, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that the Registration Statement be declared effective, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

Very truly yours,
H.C. WAINWRIGHT & CO., LLC

Show Raw Text
CORRESP
1
filename1.htm

CORRESP

 December 21, 2022

VIA EDGAR

 U.S. Securities and Exchange Commission

 Division of Corporate Finance

 Washington, DC 20549

Re:
 HTG Molecular Diagnostics, Inc.

Registration Statement on Form S-1 (Registration
No. 333-268681) -

 Concurrence in Acceleration Request

Ladies and Gentlemen:

 H.C.
Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best-efforts basis in an offering pursuant to the registration statement on Form S-1 (333-268681) (the “Registration Statement”), hereby concurs in the request by HTG Molecular Diagnostics, Inc. (the “Company”) that the effective date of the above-referenced
registration statement be accelerated to 1:00 P.M. (Eastern Time), or as soon as practicable thereafter, on December 21, 2022, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that the Registration
Statement be declared effective, pursuant to Rule 461 under the Securities Act. Wainwright affirms that it is aware of its obligations under the Securities Act as they pertain to the best efforts offering pursuant to the Registration Statement.

Very truly yours,

H.C. WAINWRIGHT & CO., LLC

By:

/s/ Edward D. Silvera

Name: Edward D. Silvera

Title: Chief Operating Officer

 430 Park Avenue | New York, NY 10022 | 212.356.0500 | www.hcwco.com

Member: FINRA/SIPC